ReportWire

Tag: Carnegie Mellon University

  • Local leaders, students react after political activist Charlie Kirk is killed at college in Utah

    [ad_1]

    The assassination of political activist Charlie Kirk is bringing condemnation from both sides of the aisle in the Pittsburgh area.

    Kirk was hosting an outdoor event at Utah Valley University when he was shot in the neck. He was taken to a hospital, where he later died.

    PREVIOUS COVERAGE >>> Conservative activist Charlie Kirk is shot and killed while speaking at a Utah college

    Several students at Carnegie Mellon University gathered to paint the Fence in tribute to Kirk.

    “When we found out he had passed away…it was a very hard moment for us. We’re all big supporters. My mom called me on the phone and was crying with me,” said Emma Gladstein with College Republicans.

    President of CMU College Republicans Anthony Cacciato said he worries people will not be able to express themselves after an event like this.

    “For anyone expressing their opinions on a college campus to be met with violence is a scary thought,” Cacciato said.

    Politicians from both sides of the aisle sent support for Kirk and his family.

    Senator Dave McCormick released a statement saying:

    Senator John Fetterman released a statement saying:

    Governor Josh Shapiro issued a statement saying:

    Download the FREE WPXI News app for breaking news alerts.

    Follow Channel 11 News on Facebook and Twitter. | Watch WPXI NOW

    [ad_2]

    Source link

  • Daily marijuana use outpaces daily drinking in the US, a new study says – Cannabis Business Executive – Cannabis and Marijuana industry news

    Daily marijuana use outpaces daily drinking in the US, a new study says – Cannabis Business Executive – Cannabis and Marijuana industry news

    [ad_1]





    Daily marijuana use outpaces daily drinking in the US, a new study says – Cannabis Business Executive – Cannabis and Marijuana industry news



























    skip to Main Content

    [ad_2]

    AggregatedNews

    Source link

  • Robotics Q&A: CMU’s Matthew Johnson-Roberson | TechCrunch

    Robotics Q&A: CMU’s Matthew Johnson-Roberson | TechCrunch

    [ad_1]

    Johnson-Roberson is one of those double threats who offers insight from two different — and important — perspectives. In addition to his long academic career, which most recently found him working as a professor at the University of Michigan College of Engineering, he also has a solid startup CV.

    Johnson-Roberson also co-founded and serves as the co-founder and CTO of robotic last-mile delivery startup Refraction AI.

    What role(s) will generative AI play in the future of robotics?

    Generative AI, through its ability to generate novel data and solutions, will significantly bolster the capabilities of robots. It could enable them to better generalize across a wide range of tasks, enhance their adaptability to new environments, and improve their ability to autonomously learn and evolve.

    What are your thoughts on the humanoid form factor?

    The humanoid form factor is a really complex engineering and design challenge. The desire to mimic human movement and interaction creates a high bar for actuators and control systems. It also presents unique challenges in terms of balance and coordination. Despite these challenges, the humanoid form has the potential to be extremely versatile and intuitively usable in a variety of social and practical contexts, mirroring the natural human interface and interaction. But we probably will see other platforms succeed before these.

    Following manufacturing and warehouses, what is the next major category for robotics?

    Beyond manufacturing and warehousing, the agricultural sector presents a huge opportunity for robotics to tackle challenges of labor shortage, efficiency, and sustainability. Transportation and last-mile delivery are other arenas where robotics can drive efficiency, reduce costs, and improve service levels. These domains will likely see accelerated adoption of robotic solutions as the technologies mature and as regulatory frameworks evolve to support wider deployment.

    How far out are true general-purpose robots?

    The advent of true general-purpose robots, capable of performing a wide range of tasks across different environments, may still be a distant reality. It requires breakthroughs in multiple fields including AI, machine learning, materials science, and control systems. The journey toward achieving such versatility is a step-by-step process where robots will gradually evolve from being task-specific to being more multi-functional and eventually general purpose.

    Will home robots (beyond vacuums) take off in the next decade?

    The next decade might witness the emergence of home robots in specific niches, such as eldercare or home security. However, the vision of having a general-purpose domestic robot that can autonomously perform a variety of household tasks is likely further off. The challenges are not just technological but also include aspects like affordability, user acceptance, and ethical considerations.

    What important robotics story/trend isn’t getting enough coverage?

    Despite significant advancements in certain niche areas and successful robotic implementations in specific industries, these stories often get overshadowed by the allure of more futuristic or general-purpose robotic narratives. The incremental but impactful successes in sectors like agriculture, healthcare, or specialized industrial applications deserve more spotlight as they represent the real, tangible progress in the field of robotics.

    [ad_2]

    Brian Heater

    Source link

  • This Fall’s COVID Vaccines Are for Everyone

    This Fall’s COVID Vaccines Are for Everyone

    [ad_1]

    Paul Offit is not an anti-vaxxer. His résumé alone would tell you that: A pediatrician at Children’s Hospital of Philadelphia, he is the co-inventor of a rotavirus vaccine for infants that has been credited with saving “hundreds of lives every day”; he is the author of roughly a dozen books on immunization that repeatedly debunk anti-vaccine claims. And from the earliest days of COVID-19 vaccines, he’s stressed the importance of getting the shots. At least, up to a certain point.

    Like most of his public-health colleagues, Offit strongly advocates annual COVID shots for those at highest risk. But regularly reimmunizing young and healthy Americans is a waste of resources, he told me, and invites unnecessary exposure to the shots’ rare but nontrivial side effects. If they’ve already received two or three doses of a COVID vaccine, as is the case for most, they can stop—and should be told as much.

    His view cuts directly against the CDC’s new COVID-vaccine guidelines, announced Tuesday following an advisory committee’s 13–1 vote: Every American six months or older should get at least one dose of this autumn’s updated shot. For his less-than-full-throated support for annual vaccination, Offit has become a lightning rod. Peers in medicine and public health have called his opinions “preposterous.” He’s also been made into an unlikely star in anti-vaccine circles. Public figures with prominently shot-skeptical stances have approvingly parroted his quotes. Right-leaning news outlets that have featured vaccine misinformation have called him up for quotes and sound bites—a sign, he told me, that as a public-health expert “you screwed up somehow.”

    Offit stands by his opinion, the core of which is certainly scientifically sound: Some sectors of the population are at much higher risk for COVID than the rest of us. But the crux of the controversy around his view is not about facts alone. At this point in the pandemic, in a country where seasonal vaccine uptake is worryingly low and direly inequitable, where health care is privatized and piecemeal, where anti-vaccine activists will pull at any single loose thread, many experts now argue that policies riddled with ifs, ands, or buts—factually sound though they may be—are not the path toward maximizing uptake. “The nuanced, totally correct way can also be the garbled-message way,” Anthony Fauci, the former director of the National Institute of Allergy and Infectious Diseases, told me.

    For the past two years, the United States’ biggest COVID-vaccine problem hasn’t been that too many young and healthy people are clamoring for shots and crowding out more vulnerable groups. It’s been that no one, really—including those who most need additional doses—is opting for additional injections at all. America’s vaccination pipeline is already so riddled with obstacles that plenty of public-health experts have become deeply hesitant to add more. They’re opting instead for a simple, proactive message—one that is broadly inclusive—in the hope that a concerted push for all will nudge at least some fraction of the public to actually get a shot this year.

    On several key vaccination points, experts do largely agree. The people who bear a disproportionate share of COVID’s risk should receive a disproportionate share of immunization outreach, says Saad Omer, the dean of UT Southwestern’s O’Donnell School of Public Health.

    Choosing which groups to prioritize, however, is tricky. Offit told me he sees four groups as being at highest risk: people who are pregnant, immunocompromised, over the age of 70, or dealing with multiple chronic health conditions. Céline Gounder, an infectious-disease specialist and epidemiologist at NYC Health + Hospitals/Bellevue, who mostly aligns with Offit’s stance, would add other groups based on exposure risk: people living in shelters, jails, or other group settings, for instance, and potentially people who work in health care. (Both Gounder and Offit also emphasize that unvaccinated people, especially infants, should get their shots this year, period.) But there are other vulnerable groups to consider. Risk of severe COVID still stratifies by factors such as socioeconomic status and race, concentrating among groups who are already disproportionately disconnected from health care.

    That’s a potentially lengthy list—and messy messaging has hampered pandemic responses before. As Gretchen Chapman, a vaccine-behavior expert at Carnegie Mellon University, told me last month, a key part of improving uptake is “making it easy, making it convenient, making it the automatic thing.” Fauci agrees. Offit, had he been at the CDC’s helm, would have strongly recommended the vaccine for only his four high-risk groups, and merely allowed everyone else to get it if they wanted to—drawing a stark line between those who should and those who may. Fauci, meanwhile, approves of the CDC’s decision. If it were entirely up to him, “I would recommend it for everyone” for the sheer sake of clarity, he told me.

    The benefit-risk ratio for the young and healthy, Fauci told me, is lower than it is for older or sicker people, but “it’s not zero.” Anyone can end up developing a severe case of COVID. That means that shoring up immunity, especially with a shot that targets a recent coronavirus variant, will still bolster protection against the worst outcomes. Secondarily, the doses will lower the likelihood of infection and transmission for at least several weeks. Amid the current rise in cases, that protection could soften short-term symptoms and reduce people’s chances of developing long COVID; it could minimize absences from workplaces and classrooms; it could curb spread within highly immunized communities. For Fauci, those perks are all enough to tip the scales.

    Offit did tell me that he’s frustrated at the way his views have frequently been framed. Some people, for instance, are inaccurately portraying him as actively dissuading people from signing up for shots. “I’m not opposed to offering the vaccine for anyone who wants it,” he told me. In the case of the young and healthy, “I just don’t think they need another dose.” He often uses himself as an example: At 72 years old, Offit didn’t get the bivalent shot last fall, because he says he’s in good health; he also won’t be getting this year’s XBB.1-targeting brew. Three original-recipe shots, plus a bout of COVID, are protection enough for him. He gave similar advice to his two adult children, he told me, and he’d say the same to a healthy thrice-dosed teen: More vaccine is “low risk, low reward.”

    The vax-for-all guideline isn’t incompatible, exactly, with a more targeted approach. Even with a universal recommendation in place, government resources could be funneled toward promoting higher uptake among essential-to-protect groups. But in a country where people, especially adults, are already disinclined to vaccinate, other experts argue that the slight difference between these two tactics could compound into a chasm between public-health outcomes. A strong recommendation for all, followed by targeted implementation, they argue, is more likely to result in higher vaccination rates all around, including in more vulnerable populations. Narrow recommendations, meanwhile, could inadvertently exclude people who really need the shot, while inviting scrutiny over a vaccine’s downsides—cratering uptake in high- and low-risk groups alike. Among Americans, avoiding a strong recommendation for certain populations could be functionally synonymous with explicitly discouraging those people from getting a shot at all.

    Offit pointed out to me that several other countries, including the United Kingdom, have issued recommendations that target COVID vaccines to high-risk groups, as he’d hoped the U.S. would. “What I’ve said is really nothing that other countries haven’t said,” Offit told me. But the situation in the U.S. is arguably different. Our health care is privatized and far more difficult to access and navigate. People who are unable to, or decide not to, access a shot have a weaker, more porous safety net—especially if they lack insurance. (Plus, in the U.K., cost was reportedly a major policy impetus.) A broad recommendation cuts against these forces, especially because it makes it harder for insurance companies to deny coverage.

    A weaker call for COVID shots would also make that recommendation incongruous with the CDC’s message on flu shots—another universal call for all Americans six months and older to dose up each year. Offit actually does endorse annual shots for the flu: Immunity to flu viruses erodes faster, he argues, and flu vaccines are “safer” than COVID ones.

    It’s true that COVID and the flu aren’t identical—not least because SARS-CoV-2 continues to kill and chronically sicken more people each year. But other experts noted that the cadence of vaccination isn’t just about immunity. Recent studies suggest that, at least for now, the coronavirus is shape-shifting far faster than seasonal flu viruses are—a point in favor of immunizing more regularly, says Vijay Dhanasekaran, a viral-evolution researcher at the University of Hong Kong. The coronavirus is also, for now, simply around for more of the year, which makes infections more likely and frequent—and regular vaccination perhaps more prudent. Besides, scientifically and logistically, “flu is the closest template we have,” Ali Ellebedy, an immunologist at Washington University in St. Louis, told me. Syncing the two shots’ schedules could have its own rewards: The regularity and predictability of flu vaccination, which is typically higher among the elderly, could buoy uptake of COVID shots—especially if manufacturers are able to bundle the immunizations into the same syringe.

    Flu’s touchstone may be especially important this fall. With the newly updated shots arriving late in the season, and COVID deaths still at a relative low, experts are predicting that uptake may be worse than it was last year, when less than 20 percent of people opted in to the bivalent dose. A recommendation from the CDC “is just the beginning” of reversing that trend, Omer, of UT Southwestern, told me. Getting the shots also needs to be straightforward and routine. That could mean actively promoting them in health-care settings, making it easier for providers to check if their patients are up to date, guaranteeing availability for the uninsured, and conducting outreach to the broader community—especially to vulnerable groups.

    Offit hasn’t changed his mind on who most needs these new COVID vaccines. But he is rethinking how he talks about it: “I will stop putting myself in a position where I’m going to be misinterpreted,” he told me. After the past week, he more clearly sees the merits of focusing on who should be signing up rather than who doesn’t need another dose. Better to emphasize the importance of the shot for the people he worries most about and recommend it to them, without reservation, to whatever extent we can.

    [ad_2]

    Katherine J. Wu

    Source link

  • New Framework Protects Consumers’ Privacy, Keeps Advertisers’ Utility

    New Framework Protects Consumers’ Privacy, Keeps Advertisers’ Utility

    [ad_1]

    Newswise — The use of mobile technologies to collect and analyze individuals’ location information has produced massive amounts of consumer location data, giving rise to an elaborate multi-billion-dollar system in which consumers can share personal data in exchange for economic benefits. But privacy risks prevail.

    In a new study, researchers used machine learning to create and test a framework that quantifies personalized privacy risks; performs personalized data obfuscation; and accommodates a variety of risks, utilities, and acceptable levels of risk-utility tradeoff. The framework outperformed prior models, significantly reducing consumers’ privacy risk while preserving advertisers’ utility.

    The study was conducted by researchers at Carnegie Mellon University (CMU), the University of Virginia, and New York University. It is published in Information Systems Research.

    “The global market for location analytics alone is projected to reach $25.5 billion by 2027,” notes Beibei Li, associate professor of IT and management at CMU’s Heinz College, who coauthored the study. “As industries increasingly unleash the power of location big data, our study offers a much-needed framework to balance privacy risks and data utilities, and to sustain a secure and self-governing multi-billion-dollar location ecosystem.”

    Massive volumes of mobile location data are being generated daily through smartphone location-based services (e.g., navigation, ride share, food delivery services). Such data track consumers’ behavior—where they eat and shop, what products they buy—to enable applications of commercial value (e.g., restaurant recommendations, location-based advertising, market research). Advertisers, who gain access to location data through data aggregators, can predict consumers’ next location with 25% success and next activity and timing with 26% success.

    But there are considerable risks to consumers of sharing location data, which includes personally identifiable information like names and home addresses. Some advertisers may carry out malicious acts using the data, usually for short-term revenue gains. Therefore, data aggregators need a personalized and flexible framework to balance diverse types of risks and utilities for different kinds of consumers and advertisers.

    In this study, researchers developed a machine learning-based framework that quantifies individual consumers’ privacy risk, quantifies advertisers’ utility, and features a personalized and flexible obfuscation scheme. The scheme suppresses a subset of locations visited by a consumer based on his or her personalized suppression parameter proportional to the individual’s risk level; it also accommodates different types and different acceptable levels of risks and utilities.

    To test their framework, researchers partnered with a leading data aggregator that integrates location data across more than 400 commonly used mobile apps (e.g., news, weather, maps, fitness) from a quarter of the U.S. population who are in compliance with privacy regulations. The data, collected in five weeks from September to October 2018, are representative of the U.S. population and the sample analyzed covers a major U.S. metropolitan area. Researchers validated the framework on a million trajectories (where and when consumers move) generated by 40,000 consumers in a major U.S. metropolitan area.

    The study’s framework accounts for distinct characteristics of individual-level location data, and outperforms multiple benchmark methods from recent studies, according to the authors.

    Using the proposed framework, the authors say, a data aggregator can effectively curtail a potential invasion of consumer privacy by performing personalized data obfuscation without sacrificing the utility of the obfuscated data to an advertiser. The aggregator may also fulfill personalized and diverse demands from both consumers and advertisers by flexibly accommodating multiple types of risks and utilities, as well as a wide array of acceptable levels of a specific risk, utility, and risk-utility tradeoff.

    “Location-based marketing is rapidly becoming a primary venue for planning marketing campaigns and targeting consumers, enriching both traditional and digital marketing strategies,” explains Meghanath Macha, a graduate of CMU’s Heinz College, who led the study. “Our framework fills a critical void and offers an important tool for the privacy-aware practices of big data location-based applications and services, providing a balance between privacy risks and data utilities.”

    Among the study’s limitations, the authors note that the data they used contain no information about individual consumers’ demographics, which would allow greater understanding of privacy issues. In addition, their proposed framework considered only one-shot data sharing with an advertiser; it did not consider more complex scenarios with multiple risks or utilities, or what happens when an advertiser combines multiple batches or sources of shared data.

    [ad_2]

    Carnegie Mellon University

    Source link

  • Shrinking hydrogels enlarge nanofabrication options

    Shrinking hydrogels enlarge nanofabrication options

    [ad_1]

    Newswise — Carnegie Mellon University’s Yongxin (Leon) Zhao and the Chinese University of Hong Kong’s Shih-Chi Chen have a big idea for manufacturing nanodevices.

    Zhao’s Biophotonics Lab develops novel techniques to study biological and pathological processes in cells and tissues. Through a process called expansion microscopy, the lab works to advance techniques to proportionally enlarge microscopic samples embedded in a hydrogel, allowing researchers to be able to view fine details without upgrading their microscopes.

    In 2019, an inspiring conversation with Shih-Chi Chen, who was visiting Carnegie Mellon as an invited speaker and is a professor at the Chinese University of Hong Kong’s Department of Mechanical and Automation Engineering, sparked a collaboration between the two researchers. They thought they could use their combined expertise to find novel solutions for the long-standing challenge in microfabrication: developing ways to reduce the size of printable nanodevices to as small as 10s of nanometers or several atoms thick.

    Their solution is the opposite of expansion microscopy: create the 3D pattern of a material in hydrogel and shrink it for nanoscale resolution.

    “Shih-Chi is known for inventing the ultrafast two-photon lithography system,” said Zhao, the Eberly Family Career Development Associate Professor of Biological Sciences. “We met during his visit to Carnegie Mellon and decided to combine our techniques and expertise to pursue this radical idea.”

    The results of the collaboration open new doors for designing sophisticated nanodevices and are published in the journal Science.

    While conventional 3D nanoscale printers focus a laser point to serially process materials and take a long time to complete a design, Chen’s invention changes the width of the laser’s pulse to form patterned light sheets, allowing for a whole image containing hundreds of thousands of pixels (voxels) to be printed at once without compromising the axial resolution.

    The manufacturing technique is called femtosecond project two-photon lithography, or FP-TPL. The method is up to 1,000 times faster than previous nanoprinting techniques and could lead to cost-effective large scale nanoprinting for use in in biotechnology, photonics or nanodevices.

    For the process, researchers would direct the femtosecond two-photon laser to modify the network structure and pore size of the hydrogel, which then creates boundaries for water-dispersible materials. The hydrogel would then be immersed in water containing nanoparticles of metal, alloys, diamond, molecular crystals, polymers or fountain pen ink.

    “Through fortuitous happenstance, the nanomaterials we tried were all attracted automatically to the printed pattern in hydrogel and assembled beautifully,” Zhao said. “As the gel shrinks and dehydrates, the materials become even more densely packed and connect to each other.”

    For example, if a printed hydrogel is placed into a silver nanoparticle solution, the silver nanoparticles self-assemble to the gel along the laser-printed pattern. As the gel dries out, it can shrink to up to 13 times its original size, making the silver dense enough to form a nano silver wire and conduct electricity, Zhao said.

    Because the gels are three-dimensional, printed patterns can be as well.

    As a demonstration of the technique’s use for encrypted optical storage — such as how CDs and DVDs are written and read with a laser — the team designed and built a seven-layer 3D nanostructure that read “SCIENCE” after it was optically decrypted.

    Each layer contained a 200×200-pixel hologram of a letter. After shrinking the sample the entire structure appears as a translucent rectangle under an optical microscope. One would need the right information on how much to expand the sample and where to shine a light through to read the information.

    “Based on our result, the technique can pack 5 petabits worth of information in a tiny cubic centimeter of space. That’s roughly 2.5 times of all U.S. academic research libraries combined.” he said.

    Zhao said that in the future the researchers’ goal is to build functional nanodevices with multiple materials.

    “In the end we would like to use the new technology to fabricate functional nanodevices, like nanocircuits, nanobiosensors, or even nanorobots for different applications,” Zhao said. “We are only limited by our imagination.”

    In addition to Zhao and Chen, co-authors on the Science paper, “3D Nanofabrication via Ultrafast Laser Patterning and Kinetically-regulated Material Assembly,” include Fei Han, Songyun Gu, Ni Zhao, all of the Chinese University of Hong Kong and Aleks Klimas, of Carnegie Mellon.

    [ad_2]

    Carnegie Mellon University

    Source link

  • In Organizations, Group Dynamics Influence Individuals’ Likelihood of Blowing the Whistle on Wrongdoing

    In Organizations, Group Dynamics Influence Individuals’ Likelihood of Blowing the Whistle on Wrongdoing

    [ad_1]

    Newswise — Wrongdoing is endemic to organizations, costing U.S. firms billions of dollars in fraud. The primary way wrongdoing is caught is through whistleblowers, who have long been thought to act out of a desire to help or improve their organization.

    A new study considered a different angle, looking at individuals as members of organizations as well as members of social groups to understand how group affiliations affect the likelihood of whistleblowing. The study found that group cohesion reduced individuals’ tendencies to blow the whistle on wrongdoers inside their group but increased their tendency to do the same on wrongdoers outside of their group.

    The study, by researchers at Carnegie Mellon University (CMU) and the University of California, Irvine (UCI), is published in Organization Science.

    Determining the Impact of Social Structure on Whistleblowing

    “Understanding the effects of group dynamics on whistleblowing can inform organizational interventions to detect and prevent wrongdoing,” explains Brandy Aven, Associate Professor of Organizational Theory, Strategy, and Entrepreneurship at CMU’s Tepper School of Business, who co-authored the study. “By understanding how individuals identify and associate with each other, we can determine the impact of social structure on responses to wrongdoing.”

    Seeing whistleblowers as individuals who act for the organization’s benefit neglects the fact that these individuals are not only members of the organization but also members of internal social groups that may form along various dimensions (e.g., work groups, demographics, rank, geography, hobbies). These social groups affect individuals’ behavior and decision-making.

    In this study, researchers used data from the 2010 Merit Principles Survey, which asked federal employees in two dozen U.S. departments and agencies about observed and hypothetical wrongdoing; the study’s sample included nearly 3,000 federal employees with knowledge of wrongdoing by another government employee who either blew the whistle or did not report the wrongdoing. The researchers also conducted a vignette experiment using a separate sample of nearly 300 online respondents in the United States.

    The study found that when a wrongdoer was affiliated with a potential whistleblower’s group, higher group cohesion decreased the likelihood of blowing the whistle, due to the potential whistleblower’s greater loyalties toward group members and a desire to protect the reputation of the group. When a wrongdoer was not affiliated with a potential whistleblower’s group, higher group cohesion increased the likelihood of blowing the whistle because potential whistleblowers felt they had the support of fellow group members, lessening fears of retaliation.

     

    “Understanding the effects of group dynamics on whistleblowing can inform organizational interventions to detect and prevent wrongdoing. By understanding how individuals identify and associate with each other, we can determine the impact of social structure on responses to wrongdoing.”

    Brandy Aven
    Associate Professor of Organizational Theory, Strategy, and Entrepreneurship

     

    Findings Suggest Individuals Are Strongly Influenced by Group Dynamics

    The authors note that their study features several limitations. While research has shown that individuals’ morality and perceptions of wrongdoing can be influenced by social dynamics and group membership, this study did not assess whether individuals interpret differently what behaviors constitute wrongdoing. The study also did not address issues related to overlapping group memberships and to differences in voluntary versus mandatory groups. Finally, the study did not distinguish which acts of wrongdoing harmed victims (e.g., harassment, discrimination) and which harmed just the organization.

    Contrary to prevailing views of whistleblowing, the study’s findings suggest that individuals are strongly influenced by group dynamics within the organization, perhaps more so than by concerns about the organization itself. Thus, while group cohesion may lead to whistleblowing in one part of the organization (i.e., outside the group), it can lead employees to shield wrongdoers in another part of the organization (i.e., inside of the group).

    “By showing how group affiliations inform whistleblowing decisions, we reveal how variation in social structure leads to heterogeneity in responses to wrongdoing,” says Patrick Bergemann, Assistant Professor of Organization and Management at the Paul Merage School of Business at UCI, who led the study. “As such, we encourage organizations to look at more than organizational-level factors and consider a new focus on relational dynamics.”

    [ad_2]

    Carnegie Mellon University

    Source link

  • How to Make Sense of This Fall’s Messy COVID Data

    How to Make Sense of This Fall’s Messy COVID Data

    [ad_1]

    It is a truth universally acknowledged among health experts that official COVID-19 data are a mess right now. Since the Omicron surge last winter, case counts from public-health agencies have become less reliable. PCR tests have become harder to access and at-home tests are typically not counted.

    Official case numbers now represent “the tip of the iceberg” of actual infections, Denis Nash, an epidemiologist at the City University of New York, told me. Although case rates may seem low now, true infections may be up to 20 times higher. And even those case numbers are no longer available on a daily basis in many places, as the CDC and most state agencies have switched to updating their data once a week instead of every day.

    How, then, is anyone supposed to actually keep track of the COVID-19 risk in their area—especially when cases are expected to increase this fall and winter? Using newer data sources, such as wastewater surveillance and population surveys, experts have already noticed potential signals of a fall surge: Official case counts are trending down across the U.S., but Northeast cities such as Boston are seeing more coronavirus in their wastewater, and the CDC reports that this region is a hotspot for further-mutated versions of the Omicron variant. Even if you’re not an expert, you can still get a clearer picture of how COVID-19 is hitting your community in the weeks ahead. You’ll simply need to understand how to interpret these alternate data sources.

    The problem with case data goes right to the source. Investment in COVID-19 tracking at the state and local levels has been in free fall, says Sam Scarpino, a surveillance expert at the Rockefeller Foundation’s Pandemic Prevention Initiative. “More recently, we’ve started to see lots of states sunsetting their reporting,” Scarpino told me. Since the Pandemic Prevention Initiative and the Pandemic Tracking Collective started publishing a state-by-state scorecard of breakthrough-case reporting in December 2021, the number of states with a failing grade has doubled. Scarpino considers this trend a “harbinger of what’s coming” as departments continue to shift resources away from COVID-19 reporting.

    Hospitalization data don’t suffer from the same reporting problems, because the federal government collects information directly from thousands of facilities across the country. But “hospitalizations often lag behind cases by a matter of weeks,” says Caroline Hugh, an epidemiologist and volunteer with the People’s CDC, an organization providing COVID-19 data and guidance while advocating for improved safety measures. Hospitalizations also don’t necessarily reflect transmission rates, which still matter if you want to stay safe. Some studies suggest, for example, that long COVID might now be more likely than hospitalization after an infection.

    For a better sense of how much the coronavirus is circulating, many experts are turning to wastewater surveillance. Samples from our sewage can provide an advanced warning of increased COVID-19 spread because everyone in a public-sewer system contributes data; the biases that hinder PCR test results don’t apply. As a result, Hugh and her colleagues at the People’s CDC consider wastewater trends to be more “consistent” than constantly fluctuating case numbers.

    When Omicron first began to wreak havoc in December 2021, “the wastewater data started to rise very steeply, almost two weeks before we saw the same rise” in case counts, Newsha Ghaeli, the president and a co-founder of the wastewater-surveillance company Biobot Analytics, told me. Biobot is now working with hundreds of sewage-sampling sites in all 50 states, Ghaeli said. The company’s national and regional dashboard incorporates data from every location in its network, but for more local data, you might need to go to a separate dashboard run by the CDC or by your state health department. Some states have wastewater surveillance in every county, while others have just a handful of sites. If your location is not represented, Ghaeli said, “the wastewater data from communities nearby is still very applicable.” And even if your county does have tracking, checking up on neighboring communities might be good practice. “A surge in a state next door … could very quickly turn into a surge locally,” Ghaeli explained.

    Ghaeli recommends watching how coronavirus levels in wastewater shift over time, rather than homing in on individual data points. Look at both “directionality” and “magnitude”: Are viral levels increasing or decreasing, and how do these levels compare with earlier points in the pandemic? A 10 percent uptick when levels are low is less concerning than a 10 percent uptick when the virus is already spreading widely.

    Researchers are still working to understand how wastewater data correlate with actual infections, because every community has unique waste patterns. For example, big cities differ from rural areas, and in some places, environmental factors such as rainfall or nearby agriculture may interfere with coronavirus tracking. Still, long-term-trend data are generally thought to be a good tool that can help sound the alarm on new surges.

    Wastewater data can help you figure out how much COVID-19 is spreading in a community and can even track all the variants circulating locally, but they can’t tell you who’s getting sick. To answer the latter question, epidemiologists turn to what Nash calls “active surveillance”: Rather than relying on the COVID-19 test results that happen to get reported to a public-health agency, actively seek out and ask people whether they recently got sick or tested positive.

    Nash and his team at CUNY have conducted population surveys in New York City and at the national level. The team’s most recent survey (which hasn’t yet been peer-reviewed), conducted from late June to early July, included questions about at-home test results and COVID-like symptoms. From a nationally representative survey of about 3,000 people, Nash and his team found that more than 17 percent of U.S. adults had COVID-19 during the two-week period—about 24 times higher than the CDC’s case counts at that time.

    Studies like these “capture people who might not be counted by the health system,” Nash told me. His team found that Black and Hispanic Americans and those with low incomes were more likely to get sick during the survey period, compared with the national estimate. The CDC and Census Bureau take a similar approach through the ongoing Household Pulse Survey.

    These surveys are “a goldmine of data,” though they need to be “carefully designed,” Maria Pyra, an epidemiologist and volunteer with the People’s CDC, told me. By showing the gap between true infections and officially reported cases, surveys like Nash’s can allow researchers to approximate how much COVID-19 is really spreading.

    Survey results may be delayed by weeks or months, however, and are typically published in preprints or news reports rather than on a health agency’s dashboard. They might also be biased by who chooses to respond or how questions are worded. Scarpino suggested a more timely option: data collected from cellphone locations or social media. The Delphi Group at Carnegie Mellon University, for example, provides data on how many people are Googling coldlike symptoms or seeking COVID-related doctor visits. While such trends aren’t a perfect proxy for case rates, they can be a helpful warning that transmission patterns are changing.

    Readers seeking to monitor COVID-19 this fall should “look as local as you can,” Scarpino recommended. That means examining county- or zip-code-level data, depending on what’s available for you. Nash suggested checking multiple data sources and attempting to “triangulate” between them. For example, if case data suggest that transmission is down, do wastewater data say the same thing? And how do the data match with local behavior? If a popular community event or holiday happened recently, low case numbers might need to be taken with a grain of salt.

    “We’re heading into a period where it’s going to be increasingly harder to know what’s going on with the virus,” Nash told me. Case numbers will continue to be undercounted, and dashboards may be updated less frequently. Pundits on Twitter are turning to Yankee Candle reviews for signs of surges. Helpful sources still exist, but piecing together the disparate data can be exhausting—after all, data reporting and interpretation should be a job for our public-health agencies, not for concerned individuals.

    Rather than accept this fragmented data status quo, experts would like to see improved public-health systems for COVID-19 and other diseases, such as monkeypox and polio. “If we get better at collecting and making available local, relevant infectious-disease data for decision making, we’re going to lead healthier, happier lives,” Scarpino said.

    [ad_2]

    Betsy Ladyzhets

    Source link

  • Computers May Have Cracked the Code to Diagnosing Sepsis

    Computers May Have Cracked the Code to Diagnosing Sepsis

    [ad_1]

    This article was originally published in Undark Magazine.

    Ten years ago, 12-year-old Rory Staunton dove for a ball in gym class and scraped his arm. He woke up the next day with a 104-degree Fahrenheit fever, so his parents took him to the pediatrician and eventually the emergency room. It was just the stomach flu, they were told. Three days later, Rory died of sepsis after bacteria from the scrape infiltrated his blood and triggered organ failure.

    “How does that happen in a modern society?” his father, Ciaran Staunton, asked me.

    Each year in the United States, sepsis kills more than a quarter million people—more than stroke, diabetes, or lung cancer. One reason for all this carnage is that if sepsis is not detected in time, it’s essentially a death sentence. Consequently, much research has focused on catching sepsis early, but the condition’s complexity has plagued existing clinical support systems—electronic tools that use pop-up alerts to improve patient care—with low accuracy and high rates of false alarm.

    That may soon change. Back in July, Johns Hopkins researchers published a trio of studies in Nature Medicine and npj Digital Medicine showcasing an early-warning system that uses artificial intelligence. The system caught 82 percent of sepsis cases and significantly reduced mortality. While AI—in this case, machine learning—has long promised to improve health care, most studies demonstrating its benefits have been conducted using historical data sets. Sources told me that, to the best of their knowledge, when used on patients in real time, no AI algorithm has shown success at scale. Suchi Saria, the director of the Machine Learning and Healthcare Lab at Johns Hopkins University and the senior author of the studies, said in an interview that the novelty of this research is how “AI is implemented at the bedside, used by thousands of providers, and where we’re seeing lives saved.”

    The Targeted Real-Time Early Warning System scans through hospitals’ electronic health records—digital versions of patients’ medical histories—to identify clinical signs that predict sepsis, alert providers about at-risk patients, and facilitate early treatment. Leveraging vast amounts of data, TREWS provides real-time patient insights and a unique level of transparency in its reasoning, according to the Johns Hopkins internal-medicine physician Albert Wu, a co-author of the study.

    Wu says that this system also offers a glimpse into a new age of medical electronization. Since their introduction in the 1960s, electronic health records have reshaped how physicians document clinical information; nowadays, however, these systems primarily serve as “an electronic notepad,” he added. With a series of machine-learning projects on the horizon, both from Johns Hopkins and other groups, Saria says that using electronic records in new ways could transform health-care delivery, providing physicians with an extra set of eyes and ears—and helping them make better decisions.

    It’s an enticing vision, but one in which Saria, the CEO of the company developing TREWS, has a financial stake. This vision also discounts the difficulties of implementing any new medical technology: Providers might be reluctant to trust machine-learning tools, and these systems might not work as well outside controlled research settings. Electronic health records also come with many existing problems, from burying providers under administrative work to risking patient safety because of software glitches.

    Saria is nevertheless optimistic. “The technology exists; the data is there,” she says. “We really need high-quality care-augmentation tools that will allow providers to do more with less.”


    Currently, there’s no single test for sepsis, so health-care providers have to piece together their diagnoses by reviewing a patient’s medical history, conducting a physical exam, running tests, and relying on their own clinical impressions. Given such complexity, over the past decade, doctors have increasingly leaned on electronic health records to help diagnose sepsis, mostly by employing a rules-based criteria—if this, then that.

    One such example, known as the SIRS criteria, says a patient is at risk of sepsis if two of four clinical signs—body temperature, heart rate, breathing rate, white-blood-cell count—are abnormal. This broadness, although helpful for catching the various ways sepsis might present itself, triggers countless false positives. Take a patient with a broken arm: “A computerized system might say, ‘Hey, look, fast heart rate, breathing fast.’ It might throw an alert,” says Cyrus Shariat, an ICU physician at Washington Hospital in California. The patient almost certainly doesn’t have sepsis but would nonetheless trip the alarm.

    These alerts also appear on providers’ computer screens as a pop-up, which forces them to stop whatever they’re doing to respond. So, despite these rules-based systems occasionally reducing mortality, there’s a risk of alert fatigue, where health-care workers start ignoring the flood of irritating reminders. According to M. Michael Shabot, a surgeon and the former chief clinical officer of Memorial Hermann Health System, “It’s like a fire alarm going off all the time. You tend to be desensitized. You don’t pay attention to it.”

    Already, electronic records aren’t particularly popular among doctors. In a 2018 survey, 71 percent of physicians said that the records greatly contribute to burnout, and 69 percent said that they take valuable time away from patients. Another 2016 study found that, for every hour spent on patient care, physicians have to devote two extra hours to electronic health records and desk work. James Adams, the chair of the Department of Emergency Medicine at Northwestern University, calls electronic health records a “congested morass of information.”

    But Adams also says that the health-care industry is at an inflection point to transform the files. An electronic record doesn’t have to simply involve a doctor or nurse putting data in, he says; instead, it “needs to transform to be a clinical-care-delivery tool.” With their universal deployment and real-time patient data, electronic records could warn providers about sepsis and various other conditions—but that will require more than a rules-based approach.

    What doctors need, according to Shabot, is an algorithm that can integrate various streams of clinical information to offer a clearer, more accurate picture when something’s wrong.


    Machine-learning algorithms work by looking for patterns in data to predict a particular outcome, like a patient’s risk of sepsis. Researchers train the algorithms on existing data sets, which helps the algorithms create a model for how that world works and then make predictions on new data sets. The algorithms can also actively adapt and improve over time, without the interference of humans.

    TREWS follows this general mold. The researchers first trained the algorithm on historical electronic-records data so that it could recognize early signs of sepsis. After this testing showed that TREWS could have identified patients with sepsis hours before they actually got treatment, the algorithm was deployed inside hospitals to influence patient care in real time.

    Saria and Wu published three studies on TREWS. The first tried to determine how accurate the system was, whether providers would actually use it, and if use led to earlier sepsis treatment. The second went a step further to see if using TREWS actually reduced patient mortality. And the third interviewed 20 providers who tested the tool on what they thought about machine learning, including what factors facilitate versus hinder trust.

    In these studies, TREWS monitored patients in the emergency department and inpatient wards, scanning through their data—vital signs, lab results, medications, clinical histories, and provider notes—for early signals of sepsis. (Providers could do this themselves, Saria says, but it might take them about 20 to 40 minutes.) If the system suspected organ dysfunction based on its analysis of millions of other data points, it flagged the patient and prompted providers to confirm sepsis, dismiss the alert, or temporarily pause the alert.

    “This is a colleague telling you, based upon data and having reviewed all this person’s chart, why they believe there’s reason for concern,” Saria says. “We very much want our frontline providers to disagree, because they have ultimately their eyes on the patient.” And TREWS continuously learns from these providers’ feedback. Such real-time improvements, as well as the diversity of data TREWS considers, are what distinguish it from other electronic-records tools for sepsis.

    In addition to these functional differences, TREWS doesn’t alert providers with incessant pop-up boxes. Instead, the system uses a more passive approach, with alerts arriving as icons on the patient list that providers can click on later. Initially, Saria was worried this might be too passive: “Providers aren’t going to listen. They’re not going to agree. You’re mostly going to get ignored.” However, clinicians responded to 89 percent of the system’s alerts. One physician interviewed for the third study described TREWS as less “irritating” than the previous rules-based system.

    Saria says that TREWS’s high adoption rate shows that providers will trust AI tools. But Fei Wang, an associate professor of health informatics at Weill Cornell Medicine, is more skeptical about how these findings will hold up if TREWS is deployed more broadly. Although he calls these studies first-of-a-kind and thinks their results are encouraging, he notes that providers can be conservative and resistant to change: “It’s just not easy to convince physicians to use another tool they are not familiar with,” Wang says. Any new system is a burden until proven otherwise. Trust takes time.

    TREWS is further limited because it only knows what’s been inputted into the electronic health record—the system is not actually at the patient’s bedside. As one emergency-department physician put it, in an interview for the third study, the system “can’t help you with what it can’t see.” And even what it can see is filled with missing, faulty, and out-of-date data, according to Wang.

    But Saria says that TREWS’s strengths and limitations complement those of health-care providers. Although the algorithm can analyze massive amounts of clinical data in real time, it will always be limited by the quality and comprehensiveness of the electronic health record. The goal, Saria adds, is not to replace physicians, but to partner with them and augment their capabilities.


    The most impressive aspect of TREWS, according to Zachary Lipton, an assistant professor of machine learning and operations research at Carnegie Mellon University, is not the model’s novelty, but the effort it must have taken to deploy it on 590,736 patients across five hospitals over the course of the study. “In this area, there is a tremendous amount of offline research,” Lipton says, but relatively few studies “actually make it to the level of being deployed widely in a major health system.” It’s so difficult to perform research like this “in the wild,” he adds, because it requires collaborations across various disciplines, from product designers to systems engineers to administrators.

    As such, by demonstrating how well the algorithm worked in a large clinical study, TREWS has joined an exclusive club. But this uniqueness may be fleeting. Duke University’s Sepsis Watch algorithm, for one, is currently being tested across three hospitals following a successful pilot phase, with more data forthcoming. In contrast with TREWS, Sepsis Watch uses a type of machine learning called deep learning. Although this can provide more powerful insights, how the deep-learning algorithm comes to its conclusions is unexplainable—a situation that computer scientists call the black-box problem. The inputs and outputs are visible, but the process in between is impenetrable.

    On the one hand, there’s the question of whether this is really a problem: Doctors don’t always know how drugs work, Adams says, “but at some point, we have to trust what the medicine is doing.” Lithium, for example, is a widely used, effective treatment for bipolar disorder, but nobody really understands exactly how it works. If an AI system is similarly useful, maybe interpretability doesn’t matter.

    Wang suggests that that’s a dangerous conclusion. “How can you confidently say your algorithm is accurate?” he asks. After all, it’s difficult to know anything for sure when a model’s mechanics are a black box. That’s why TREWS, a simpler algorithm that can explain itself, might be a more promising approach. “If you have this set of rules,” Wang says, “people can easily validate that everywhere.”

    Indeed, providers trusted TREWS largely because they could see descriptions of the system’s process. Of the clinicians interviewed, none fully understood machine learning, but that level of comprehension wasn’t necessary.


    In machine learning, although the specific algorithmic design is important, the results have to speak for themselves. By catching 82 percent of sepsis cases and reducing time to antibiotics by 1.85 hours, TREWS ultimately reduced patient deaths. “This tool is, No. 1, very good; No. 2, received well by clinicians; and No. 3, impacts mortality,” Adams says. “That combination makes it very special.”

    However, Shariat, the ICU physician at Washington Hospital in California, was more cautious about these findings. For one, these studies only compared patients with sepsis who had the TREWS alert confirmed within three hours to those who didn’t. “They’re just telling us that this alert system that we’re studying is more effective if someone responds to it,” Shariat says. A more robust approach would have been to conduct a randomized controlled trial—the gold standard of medical research—where half of patients got TREWS in their electronic record while the other half didn’t. Saria says that randomization would have been difficult to do given patient-safety concerns, and Shariat agrees. Even so, he says that the absence “makes the data less rigorous.”

    Shariat also worries that the sheer volume of alerts, with about two out of three being false positives, might contribute to alert fatigue—and potentially overtreatment with fluids and antibiotics, which can lead to serious medical complications such as pulmonary edema and antibiotic resistance. Saria acknowledges that TREWS’s false-positive rate, although lower than that of existing electronic-health-record systems, could certainly improve, but says it will always be crucial for clinicians to continue to use their own judgment.

    The studies also have a conflict of interest: Saria is entitled to revenue distribution from TREWS, as is Johns Hopkins. “If this goes prime time, and they sell it to every hospital, there’s so much money,” Shariat says. “It’s billions and billions of dollars.”

    Saria maintains that these studies went through rigorous internal and external review processes to manage conflicts of interest, and that the vast majority of study authors don’t have a financial stake in this research. Regardless, Shariat says it will be crucial to have independent validation to confirm these findings and ensure the system is truly generalizable.

    The Epic Sepsis Model, a widely used algorithm that scans through electronic records but doesn’t use machine learning, is a cautionary example here, according to David Bates, the chief of general internal medicine at Brigham and Women’s Hospital. He explains that the model was developed at a few health systems with promising results before being deployed at hundreds of others. The model then deteriorated, missing two-thirds of patients with sepsis and having a concerningly high false-positive rate. “You can’t really predict how much the performance is going to degrade,” Bates says, “without actually going and looking.”

    Despite the potential drawbacks, Orlaith Staunton, Rory’s mother, told me that TREWS could have saved her son’s life. “There was complete breakdown in my son’s situation,” she said; none of his clinicians considered sepsis until it was too late. An early-warning system that alerted them about the condition, she added, “would make the world of difference.”

    After Rory’s death, the Stauntons started the organization End Sepsis to ensure that no other family would have to go through their pain. In part because of their efforts, New York State mandated that hospitals develop sepsis protocols, and the CDC launched a sepsis-education campaign. But none of this will ever bring back Rory, Ciaran Staunton said: “We will never be happy again.”

    This research is personal for Saria as well. Almost a decade ago, her nephew died of sepsis. By the time it was discovered, there was nothing his doctors could do. “It all happened too quickly, and we lost him,” she says. That’s precisely why early detection is so important—life and death can be mere minutes away. “Last year, we flew helicopters on Mars,” Saria says, “but we’re still freaking killing patients every day.”

    [ad_2]

    Simar Bajaj

    Source link